Hepatoprotective Effect of Gamma-mangostin for Amelioration of Impaired Liver Structure and Function in Streptozotocin-induced Diabetic Mice

The aim of this study was to investigate whether gamma-mangostin could reduce fasting blood glucose, cholesterol, SGOT, SGPT, and also ameliorate damaged hepatocytes in diabetic mice. In this study, we used male BALB/C mice. Mice were divided into two groups: normal control (KN) and streptozotocin-i...

Full description

Saved in:
Bibliographic Details
Published in:IOP conference series. Earth and environmental science 2019-01, Vol.217 (1), p.12031
Main Authors: Husen, S A, Winarni, D, Salamun, Ansori, A N M, Susilo, R J K, Hayaza, S
Format: Article
Language:English
Subjects:
Acarbose
Amelioration
Antioxidants
Blood
Blood glucose
Body weight
Cholesterol
Diabetes
Diabetes mellitus
Diabetic Mice
Fasting
Gamma-mangostin
Glucose
Hepatocytes
Liver
Liver Structure
Rodents
Streptozocin
Streptozotocin
Structure-function relationships
Subgroups
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The aim of this study was to investigate whether gamma-mangostin could reduce fasting blood glucose, cholesterol, SGOT, SGPT, and also ameliorate damaged hepatocytes in diabetic mice. In this study, we used male BALB/C mice. Mice were divided into two groups: normal control (KN) and streptozotocin-induced diabetic. Streptozotocin (STZ) induction was performed using multiple low doses of 30 mg/kg body weight injected for five consecutive days. The diabetic mice were separated into three subgroups: diabetic control (KD), diabetic mice treated with acarbose (KA), and diabetic mice treated with gamma-mangostin at either 0,5 mg/kg body weight (P1), 1 mg/kg body weight (P2), or 2 mg/kg body weight (P3). Before and after STZ injection, fasting blood glucose and cholesterol level would be observed. Fasting blood glucose and cholesterol level were also measured at the 1st, 7th, and 14th day of gamma-mangostin treatment. Treatment was given for 14 days. On the 15th day, SGOT and SGPT were measured using a Pentra C 200 Reader, while the liver was collected and processed onto the histological slides. Interestingly, we found that gamma-mangostin was able to reduce the fasting blood glucose, cholesterol, SGOT, SGPT, and ameliorate the damaged hepatocytes in significant diabetic mice. Therefore, we concluded that gamma-mangostin is a promising anti-diabetic agent due to its anti-hyperglycemic and antioxidant activities.
ISSN:1755-1307
1755-1315
1755-1315
DOI:10.1088/1755-1315/217/1/012031